{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"28"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"30"}],"units":"Participants"}],"description":"Response that was confirmed on 2 consecutive evaluations after 8 months of treatment.\n\nCR, nCR and VGPR as defined in the primary outcome.\n\nPartial Response(PR): \\>=50% reduction in serum M-component and/or\n\nUrine M-Component \\>=90% reduction or \\<200mg per 24hours; or \\>=50% decrease in difference between involved and uninvolved FLC levels.","groups":[{"description":"Bortezomib 1.3mg/m\\^2 by IV days 1, 4, 8 \\& 11\n\nCyclophosphamide 300mg/m\\^2 PO days 1, 8, 15 \\& 22\n\nDexamethasone 40mg PO days 1-4, 9-12, 17-20","id":"OG000","title":"CyBorD (Bortezomib 1.3mg/m^2)"},{"description":"Bortezomib 1.5mg/m\\^2 by IV days 1, 8, 15 \\& 22\n\nCyclophosphamide 300mg/m\\^2 PO days 1, 8, 15 \\& 22\n\nDexamethasone 40mg PO cycle 1-2 days 1-4, 9-12, 17-20, cycle 3 and beyond days 1, 8, 15 \\& 22","id":"OG001","title":"CyBorD (Bortezomib 1.5mg/m^2)"}],"paramType":"NUMBER","populationDescription":"Participants who received 4 cycles of treatment were analyzed.","reportingStatus":"POSTED","timeFrame":"4 cycles","title":"Number of Participants Who Responded to Treatment (Complete Response,CR; Near Complete Response, nCR; Very Good Partial Response, VGPR; or Partial Response, PR) After 4 Cycles","type":"SECONDARY","unitOfMeasure":"participants"}